Boston Scientific and Accenture Develop Data-Driven Digital Heart Failure Management Service in Parts of Europe to Help Improve Patient Outcomes and Reduce Cost of Treating Chronic Cardiovascular Conditions
Care Pathway Transformation solution is designed to enable providers to make better-informed decisions based on patient population insights with a new Heart Failure Management Service
Boston Scientific Corporation and Accenture have developed a cloud-based, data-driven digital Heart Failure Management Service for hospitals that is designed to help improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases.
The solution, known as ADVANTICS™ Care Pathway Transformation, is designed to enable providers to make more proactive and informed decisions based on insights into the patient population, ultimately improving the care a patient experiences from hospital stay through post-discharge care and in-home support.
The Care Pathway Transformation solution uses the Accenture analytics insights platform, which provides actionable insights into care coordination and patient population health patterns, revealing opportunities to improve their consistency and efficiency. The solution will focus on three key measurements:
- Pathway Analytics: how a patient moves through the hospital system, how long each step takes and whether a patient can be better served by a more efficient system;
- Care Management: how patients are diagnosed, treated and monitored, by whom and how often, as well as their ongoing vital signs and risk analysis; and
- Patient Engagement: how patients are educated, monitored and receive communication during their hospitalization and after discharge.
The new heart failure management service solution has been tailored for insight into patients with heart failure, but the companies plan to expand it to additional disease states.
In developing this solution, both companies worked with two of the largest hospitals in Scandinavia, Karolinska University Hospital in Sweden and Tampere Heart Hospital in Finland, to assess the current state of care delivery for heart failure patients and identify opportunities for improvement at each hospital. Heart failure has been identified as one of the costliest disease states to manage—resulting in about two percent of healthcare spending and accounting for an average 11-day hospital stay in Europei.
“The collaboration with Boston Scientific and Accenture exposed significant opportunities to increase provider collaboration and improve the quality of care that patients experience when coming to our hospital,” said Dr. Kari Niemelä, chief executive officer, Tampere Heart Hospital. “For example, we identified a 25 percent unnecessary heart failure readmissions rate, and therefore a definite need for better care coordination, supported by modern technology and processes that can decrease overall costs.”
“Boston Scientific and Accenture designed this digital health platform to help providers standardize care, reduce overall length of stay and lower readmission rates,” said Mike Mahoney, president and chief executive officer, Boston Scientific. “The Care Pathway Transformation solution is designed to support healthcare professionals and patients to have more informed relationships, leading to better health outcomes and lower costs for health systems. Together, we are addressing an acute need for some of the most costly chronic conditions.”
Anne O’Riordan, senior managing director at Accenture Life Sciences, said, “Socio-economic changes are driving the market to move to value-based care, and new data-driven care transformation services are a great enabler of delivering high-quality healthcare at the right cost. Working together with Boston Scientific, we are able to bring to market digital capabilities and analytics-driven insights that focus on improving patient and economic outcomes.”
Boston Scientific and Accenture initially plan to make the Care Pathway Transformation solution available to hospitals in the United Kingdom and Scandinavia and expect to pilot projects throughout Europe and the United States soon.